The short version of Visceral adipose tissue fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-27 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Thomson further explained that ions are atoms that have a surplus or shortage of electrons. Thomson's model is popularly known as the plum pudding model, based on the idea that the electrons are distributed throughout the sphere of positive charge with the same density as raisins in a plum pudding. Neither Thomson nor his colleagues ever used this analogy. It seems to have been a conceit of popular science writers. The analogy suggests that the positive sphere is like a solid, but Thomson likened it to a jelly, as he proposed that the electrons moved around in it in patterns governed by the electrostatic forces. The positive electrification in Thomson's model was a temporary concept, which he hoped would ultimately be explained by some phenomena of the electrons. Like all atomic models of that time, Thomson's model was incomplete, it could not predict any of the known properties of the atom such as emission spectra. In 1910, Robert A. Millikan and Harvey Fletcher reported the results of their oil drop experiment in which they isolated and measured the charge of an electron. Careful measurements over several years gave the charge -4.774 × 10−10esu.
The company opened new offices in Singapore and Hong Kong in 1927 and in Taiwan in 1929 to distribute its product throughout Southeast Asia. Between 1920 and 1929, revenue from the seasoning's sales rose from nearly 3 million yen to 10 million yen, largely due to increased exports of the product to foreign markets. To lower the cost of mass production, the seasoning's wheat was replaced with soybeans, as the price of the latter at the time was lower than the former's. In the United States, the seasoning, labeled by the FDA as a "Vegetable Protein Derivative", sold poorly on the consumer market, but Ajinomoto expanded their operations in the United States in 1931 due to mass orders of the seasoning by H.J. Heinz, Co. and Campbell Soup Co. Between 1931 and 1937, seasoning production increased from 1,077 tons to 3,750 tons, with revenue rising from 13 million yen to 27 million yen. Due to Japan's increasing isolationism in the late 1930s, the production of AJI-NO-MOTO decreased from 3,750 tons in 1937 to 2,339 tons in 1940. By 1942, production of the seasoning was reduced to 1,000 tons before completely stopping by 1944 due to World War II.
Rita Kempley, writing in The Washington Post, said actor Washington gave a "zealous, Oscar-caliber performance as this African messiah, who was recognized as one of South Africa's major political voices when he was only 25." Also writing for The Washington Post, Desson Howe thought the film "could have reached further" and felt the story centring on Woods's character was "its major flaw". He saw director Attenborough's aims as "more academic and political than dramatic". Overall, he expressed his disappointment by exclaiming, "In a country busier than Chile with oppression, violence and subjugation, the story of Woods' slow awakening is certainly not the most exciting, or revealing." Roger Ebert in the Chicago Sun-Times offered a mixed review calling it a "sincere and valuable movie" while also exclaiming, "Interesting things were happening, the performances were good and it is always absorbing to see how other people live." But on a negative front, he noted how the film "promises to be an honest account of the turmoil in South Africa but turns into a routine cliff-hanger about the editor's flight across the border. It's sort of a liberal yuppie version of that Disney movie where the brave East German family builds a hot-air balloon and floats to freedom." Janet Maslin writing in The New York Times saw the film as "bewildering at some points and ineffectual at others" but pointed out that "it isn't dull.
Sources: en.wikipedia.org
Arizona reports its first death of the Sin Nombre strain of hantavirus pulmonary syndrome. Actor James Handy is killed in his Los Angeles home following a fatal stabbing wound. The son of Handy's girlfriend is later arrested. Gallup releases a poll saying support for same-sex marriage in the U.S. has declined after two decades of growth, with 65% of adults saying it should be legal, down from 71% in 2022 and 2023. June 4 The Kennedy Center orders staff to remove all references to Donald Trump's name from the building following a court ruling. Arizona Attorney General Kris Mayes says she will seek new indictments against fake electors involved in attempting to overturn the 2020 election in the state following a denial of an appeal by Mayes that would require prosecutors to send the case back to the grand jury. The U.S. House passes legislation to provide new aid to Ukraine and new sanctions on Russia. ICE ends a Biden-era policy to report detainee deaths that occur within 30 days of leaving custody. June 5 Federal judge John McConnell Jr. strikes down the Trump administration’s policy that halted asylum and green card proceedings for applicants from 39 countries. The ruling states ICE's actions are arbitrary and capricious and ignore the law. The National Football League's Chicago Bears vote to advance plans for stadium development in Hammond in northwest Indiana to replace Soldier Field as its home stadium. However, the site of the stadium still remains determined. The FDA says that Target has recalled two types of baby wipes due to bacterial contamination.
BMPs for clinical use are produced using recombinant DNA technology (recombinant human BMPs; rhBMPs). Recombinant BMP-2 and BMP-7 are currently approved for human use. rhBMPs are used in oral surgeries. BMP-7 has also recently found use in the treatment of chronic kidney disease (CKD). BMP-7 has been shown in murine animal models to reverse the loss of glomeruli due to sclerosis. A 2022 study by researchers from the Mayo Clinic, Maastricht University, and Ethris GmBH, a biotech company that focuses on RNA therapeutics, found that chemically modified mRNA encoding BMP-2 promoted dosage-dependent healing of femoral osteotomies in male rats. The mRNA molecules were complexed within nonviral lipid particles, loaded onto sponges, and surgically implanted into the bone defects. They remained localized around the site of application. Compared to receiving rhBMP-2 directly, bony tissues regenerated after mRNA treatment displayed superior strength and less formation of massive callus.
Owing to the low abundance of actinides, their extraction is a complex, multistep process. Fluorides of actinides are usually used because they are insoluble in water and can be easily separated with redox reactions. Fluorides are reduced with calcium, magnesium or barium:
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.